Sermorelin / GHRP-6 / GHRP-2 Blend

This blend adds GHRP-6, a ghrelin-receptor agonist known for pronounced appetite stimulation, to the sermorelin/GHRP-2 combination. It is discussed mainly in the context of protocols emphasizing both GH release and increased caloric intake, such as informal mass-gain research. Because GHRP-6 and GHRP-2 both act at the ghrelin receptor, combining them targets an overlapping pathway rather than two distinct mechanisms, and the added benefit of using both together over either alone has not been directly studied. Sermorelin and GHRP-2 individually carry a longer research history; GHRP-6's appetite-driving properties are well documented, but the specific triple combination has limited dedicated research. It is not approved for human medical use. Reported benefits include stimulates a strong growth-hormone pulse, associated with pronounced appetite stimulation, useful in mass-gain-oriented research contexts, supports recovery.

Reported ranges run 300-700 mcg. A low protocol is 300 mcg 2-3 times daily, and a high protocol is 700 mcg 2-3 times daily. This is reference information, not a dosing recommendation.

All three components are short-acting: sermorelin at roughly 10-20 minutes, GHRP-6 and GHRP-2 both at roughly 30-60 minutes, requiring multiple daily doses.. That is what sets the dosing frequency, and it is why the timing guidance is ~30 min before bed, empty stomach.

Subcutaneous: into fat, under the skin. Injected subcutaneously, generally 2-3 times daily; the pronounced appetite effect of GHRP-6 leads many protocols to time doses around meals.

8-12 weeks on, followed by 4 weeks off. The pronounced appetite effect is often used as a practical cue for meal timing rather than a reason to shorten the cycle.

Reported side effects include pronounced increase in hunger, water retention, flushing, lethargy, injection site irritation. Evidence level for this compound is moderate evidence.